-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.P1.63 634. Myeloproliferative Syndromes: Clinical: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, AML, Biological, Coronaviruses, SARS-CoV-2/COVID-19, Bleeding and Clotting, Diseases, Non-Biological, Combinations, Elderly, Therapies, blood banking, MPN, Thrombosis, Polycythemia vera, thrombocythemia, Study Population, Thromboembolism, Clinically relevant, Myeloid Malignancies, pharmacology, pathways
Saturday, December 5, 2020: 7:00 AM-3:30 PM

Cem Akin, MD, PhD1*, Hanneke Oude Elberink, MD, PhD2*, Jason Gotlib, MD, MS3, Vito Sabato, MD, PhD4*, Karin Hartmann, MD5*, Sigurd Broesby-Olsen, MD6*, Mariana Castells, MD, PhD7*, Tsewang Tashi, MD8*, Mark L. Heaney, MD9, Tracy I. George, MD10, Frank Siebenhaar, MD11*, Deepti H. Radia, MRCPI, FRCPath12*, Massimo Triggiani, MD, PhD13*, Paul van Daele, MD14*, Daniel J. DeAngelo, MD, PhD15, Oleg Schmidt-Kittler, PhD16*, Hui-Min Lin, PhD16*, Andrew Morrison, BS16*, Brenton G. Mar, MD, PhD16* and Marcus Maurer, MD11*

1University of Michigan, Ann Arbor, MI
2Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
3Division of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA
4Department of Immunology, Allergology and Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
5Division of Allergy, University of Basel, Basel, Switzerland
6Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
7Brigham and Women’s Hospital, Boston, MA
8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
9Columbia University Medical Center, New York, NY
10ARUP Laboratories, University of Utah, Salt Lake City, UT
11Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany
12Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
13Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy
14Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
15Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
16Blueprint Medicines Corporation, Cambridge, MA

Lin-Pierre Zhao, MD1*, Rafael Daltro De Oliveira, MD1*, Clemence Marcault2*, Juliette Soret, MD3*, Nicolas Gauthier, MD4*, Emmanuelle Verger, PhD5*, Nabih Maslah, PharmD5,6*, Blandine Roux, MSc7*, Nathalie Parquet, MD8*, Christine Dosquet, MD5*, Delphine Rea, MD, PhD8, Jean-Marc Zini, MD9*, William Vainchenker8*, Emmanuel Raffoux, MD8*, Stephane Giraudier, MD, PhD5,6*, Bruno Cassinat, PharmD, PhD5,10*, Jean-Jacques Kiladjian, MD, PhD11,12* and Lina Benajiba, MD, PhD1,13*

1Université de Paris, Clinical Investigations Center, Saint-Louis hospital, APHP, Paris, France
2Saint-Louis, Nice, France
3Centre d'Investigations Cliniques, Hôpital Saint-Louis; Assistance Publique – Hôpitaux de Paris; Université de Paris, Paris, France
4Centre d'Investigations Cliniques (INSERM CIC 1427), AP-HP, Hopital Saint-Louis, Université de Paris, Paris, FRA
5Université de Paris, Cellular biology Department, Saint-Louis hospital, APHP, Paris, France
6UMRS_1131, Inserm, Université de Paris, Institut de recherche Saint-Louis, Paris, France
7INSERM UMR 944, Saint-Louis Research Institute, Paris, France
8Université de Paris, Hematology department, Saint-Louis hospital, APHP, Paris, France
9Université de Paris, Hematology department, Saint-Louis hospital, APHP, Paris, FRA
10Institut de Recherche St Louis, Université de Paris, INSERM U1131, Paris, France
11INSERM UMR 1131, Saint-Louis Research Institute, Paris, France
12Université de Paris, Clinical Investigations Center, Saint-Louis hospital, APHP, Paris, FRA
13APHP, INSERM U944, Institute of Hematology - St Louis Hospital, PARIS, France

Mark W. Drummond, PhD, FRCPath1*, Charlotte Gaskell, BSc, MSc2*, Claire Harrison, DM, FRCPath3, Adam J. Mead, MD, PhD4, Christina Yap, PhD, CStat2,5*, Aimee E Jackson, BSc, MSc2*, Jennifer Byrne, FRCP, FRCPath, PhD6*, Fiona J Clark, FRCP, FRCPath7*, Srinivasan Narayanan, FRCP, FRCPath8*, David Bowen, MD9, Tim C.P Somervaille, PhD, FRCP, FRCPath10,11, Emma Gudgin, MBBS, MRCP, FRCPath, PhD12*, Dragana Milojkovic13*, Rachel S Fletcher, PhD2*, Charlotte K Brierley, MRCP, MD14* and Steve Knapper, BMBCh, MRCP, FRCPath, DM15

1Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
2Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
3Guy's and St Thomas' Hospital, London, United Kingdom
4MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
5Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, United Kingdom
6Centre for Clinical Haematology, Nottingham University Hospitals Trust, Nottingham, ENG, United Kingdom
7Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
8Department of Haematology, University Hospital Southampton NHSFT, Southampton, United Kingdom
9St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom
10The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
11The Christie Hospital, Cancer Research UK Manchester Institute, Manchester, United Kingdom
12Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom
13Department of Haematology, Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom
14MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
15Division of Cancer & Genetics, Cardiff University, Cardiff, United Kingdom

Claudia Lebedinsky, MD1, Stephen P. Anthony, DO2, Golam Mohi, PhD3, Huyuan Yang, PhD1*, Jian Mei, PharmD1* and Edgar Braendle, MD1

1Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA
2Sumitomo Dainippon Pharma Oncology, Inc., Lehi, UT
3Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA

Paola Guglielmelli, MD1, Jean-Jacques Kiladjian, MD, PhD2*, Alessandro Vannucchi, MD1, Ming-hui Duan, MD3*, Haitao Meng, MD, PhD4*, Ling Pan, MD, PhD5*, Guangsheng He, MD, PhD6*, Srdan Verstovsek, MD, PhD7, Françoise Boyer-Perrard, MD8*, Fiorenza Barraco, MD9*, Dietger Niederwieser, MD, PhD10, Ester Pungolino11*, Anna Marina Liberati, MD12, Claire Harrison, DM, FRCPath13, Pantelia Roussou, MSc14*, Monika Wroclawska, MD14*, Kevin Majidi14*, Peter AW te Boekhorst, MD, PhD15* and Heinz Gisslinger, MD16*

1CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera–Universitaria Careggi, University of Florence, Florence, Italy
2Hôpital Saint-Louis et Université Paris Diderot, Paris, France
3Peking Union Medical College Hospital, Beijing, China
4Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University; Institute of Hematology, Zhejiang University, Zhejiang, China
5West China Hospital of Sichuan University, Chengdu, China
6The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Jiangsu, China
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
8Centre Hospitalier Universitaire d’Angers, Angers, France
9Centre Hospitalier Universitaire Lyon Sud, Lyon, France
10Department of Hematology and Oncology, University Leipzig, Leipzig, Germany
11Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
12Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy
13Department of Clinical Haematology, Guys and St Thomas NHS Trust, London, United Kingdom
14Novartis Pharma AG, Basel, Switzerland
15Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
16Haematologie Haemostaseologie Innere Medizin I, AKH Allgemeines Krankenhaus Wien, Vienna, Austria

Daniel Rivera, MD1*, Srdan Verstovsek, MD, PhD1, Prithviraj Bose, MD1, Naveen Pemmaraju, MD1, Lingsha Zhou1*, Sherry A. Pierce, BSN, BA1*, Hagop M. Kantarjian, MD2, Zeev E. Estrov, MD1 and Lucia Masarova, MD1*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

John Mascarenhas, MD1,2,3,4,5, Heidi E. Kosiorek, MS6,7*, Lilian Varricchio, PhD8*, Rupali Bhave, M.D.9*, Andrew T. Kuykendall, MD10,11,12,13, Rami Komrokji, MD14, Aaron T. Gerds, MD, MS15,16,17,18,19,20,21,22,23,24, Jeanne M. Palmer, Md25,26,27, Amelia R. Gabler1,28,29,30,31,32*, Lonette Sandy33*, Anna Rita Migliaccio, PhD34,35,36,37, Mohamed E Salama, MD38,39, Rona Singer Weinberg, PhD40, Maureen O'Connor-McCourt, PhD41*, Gilles Tremblay, PhD42*, Paul I. Nadler, MD43, Amylou C. Dueck, PhD2,44,45,46, Ruben A. Mesa, MD, FACP47 and Ronald Hoffman, MD2,48,49,50

1Icahn School of Medicine at Mount Sinai, New York, NY
2MPN Research Consortium, New York, NY
3Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
4Hematology, Mount Sinai School of Medicine, New York, NY
5Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
6Mayo Clinic, Scottsdale, AZ
7Department of Biostatistics, Mayo Clinic, Phoenix, AZ
8Division of Hematology and Oncology, Tish Cancer Institute, Ichan School of Medicine at Mount Sinai, New York
9Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC
10Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
11Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
12Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
13Moffitt Cancer Center, University of South Florida, Tampa, FL
14Moffitt Cancer Center, Tampa, FL
15Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
16Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH
17Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
18Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
19Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
20Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
21Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH
22Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
23Cleveland Clinic Taussig Cancer Institute, Shaker Heights, OH
24Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
25Mayo Clinic, Phoenix, AZ
26Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ
27Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
28Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY
29Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, New York, NY
30Icahn School of Medicine at Mount Sinai, Myeloproliferative Neoplasms Research Consortium, New York, NY
31Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
32Memorial Sloan Kettering Cancer Center, New York, NY
33Ichan School of Medicine At Mount Sinai, New York City, NY
34Biomedical and Neuromotorial Sciences, Alma Mater Studiorum University, Bologna, Italy
35Department of Biomedical and Neuromotorial Sciences, Mount Sinai School of Medicine, New York, NY
36Division of Hematology/Oncology, Tisch Cancer Institute, Ichan School of Medicine at Mount Sinai, New York, Italy
37Myeloproliferative Neoplasm-Research Consortium, New York, NY
38Mayo Medical Laboratories, Rochester, MN
39Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
40New York Blood Center, New York, NY
41Forbius, Montreal, Canada
42Formation Biologics, Montreal, QC, Canada
43Nadler Pharma Associates, LLC, Randolph, NJ
44Mayo Clinic Arizona, Phoenix, AZ
45Section of Biostatistics, Mayo Clinic, Scottsdale, AZ
46Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ
47Mays Cancer Center at UT Health San Antonio, San Antonio, TX
48Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
49Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
50Hematology/Oncology, Mount Sinai School of Medicine, New York, NY

Kimberley Dilley, MD, MPH1*, Jason Harb, PhD2*, Muhammad Jalaluddin, PhD2*, Jessica E. Hutti, PhD1* and Jalaja Potluri, MD1

1AbbVie Inc., North Chicago, IL
2AbbVie, Inc., North Chicago, IL

Peter AW te Boekhorst, MD, PhD1*, Alexandre Theocharides, MD2*, Heinz Gisslinger, MD3*, Timothy Devos, MD4, Eric Lippert, MD, PhD5*, Damianos Sotiropoulos, MD6, Miklos Egyed, MD, PhD7*, Valerio De Stefano, MD8*, Vincenzo Accurso, MD9*, Alessandra Iurlo, MD, PhD10*, Anders E.A. Dahm, MD, PhD11*, Regina Garcia-Delgado, MD12*, Nathan Cantoni, MD13*, Mike Zuurman, PhD14*, Michael Zaiac, MD15*, Erik Houtsma, MSc16*, Amir Iqbal, PhD16*, Paola Di Matteo, MD, PhD17* and Alberto Alvarez-Larrán, MD18*

1Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
2Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
3Haematologie Haemostaseologie Innere Medizin I, AKH Allgemeines Krankenhaus Wien, Vienna, Austria
4Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium; Division of Hematology, University Hospitals Leuven, Leuven, Belgium
5Service Hématologie - Bat 3, Hôpital Morvan - CHU de Brest, Brest, France
6Heamatology Clinic, General Hospital of Thessaloniki G Papanikolaou, Thessaloniki, Greece
7Hematológiai Osztály, Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary
8Section of Hematology, Catholic University, Fondazione Policlinico A Gemelli IRCCS, Rome, Italy
9U O di Ematologia Divisione di Oncologia, Az Osp Univ Policlinico P Giaccone Universita Studi Palermo, Palermo, Italy
10Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
11Avdeling for blodsykdommer, Akershus universitetssykehus, Lørenskog, Norway
12Servicio de Hematologia, Hospital Virgen de la Victoria, Malaga, Spain
13Main Centre, Kantonsspital Aarau AG, Aarau, Switzerland
14Novartis Pharma BV, Amsterdam, Gelderland, Netherlands
15Novartis Pharma AG, Basel, Switzerland
16Novartis Global Service Center, Dublin, Ireland
17Novartis Farma S.p.A, Origgio, Italy
18Servicio de Hematologia, Hospital Clinic de Barcelona - GEMFIN, Barcelona, Spain

Blake T. Langlais, MS1*, Carolyn Mead-Harvey, MS1*, Heidi E. Kosiorek, MS1*, Gina L. Mazza, PhD1*, Ruben Mesa, MD2, Jeanne M. Palmer, Md3 and Amylou C. Dueck, PhD1

1Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ
2Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
3Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

Michael R. Grunwald, MD1, Ivy Altomare, MD2*, Robyn M. Scherber, MD3,4, Patricia Kalafut, PhD3*, Haobo Ren, PhD3* and Srdan Verstovsek, MD, PhD5

1Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
2Division of Medical Oncology, Duke University Medical Center, Durham, NC
3Incyte Corporation, Wilmington, DE
4UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Orly Leiva, MD1, Olesya Baker, PhD2*, Andrew M. Brunner3*, Hanny Al-Samkari, MD4, Rebecca Karp Leaf, MD5, Rachel P. Rosovsky, MD, MPH6, Amir T. Fathi, M.D.7, James I Weitzman, MD8, Larissa Bornikova, MD9*, Valentina Nardi, MD10 and Gabriela S. Hobbs, MD11

1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
2Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA
3Center for Leukemia, Massachusetts General Hospital, Boston, MA
4Division of Hematology, Massachusetts General Hospital, Dana-Farber Cancer Institute, Harvard University, Boston, MA
5Massachusetts General Hospital, Boston, MA
6Division of Hematology, Massachusetts General Hospital, Boston, MA
7Massachusetts General Hospital , Harvard Medical School, Cambridge, MA
8MGH/North Shore Cancer Center, Danvers, MA
9Hematology/Oncology, Massachusetts General Hospital, Boston, MA
10Department of Pathology, Massachusetts General Hospital, Boston, MA
11Leukemia Center, Massachusetts General Hospital, Boston, MA

Sangeetha Venugopal, MD1, Srdan Verstovsek, MD, PhD1, Prithviraj Bose, MD1, Naveen Pemmaraju, MD1, Lingsha Zhou1*, Sherry A. Pierce, BSN, BA1*, Hagop M. Kantarjian, MD2, Zeev E. Estrov, MD1 and Lucia Masarova, MD1*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Joan How, MD1, Yiwen Liu2*, Jennifer Lombardi Story3*, Donna S. Neuberg, ScD4, Katya Ravid, PhD, DSc5, Wolfgang Jarolimek6*, Brett Charlton6* and Gabriela S. Hobbs, MD3

1Dana Farber Cancer Institute / Massachusetts General Hospital, Boston, MA
2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
3Leukemia Center, Massachusetts General Hospital, Boston, MA
4Data Sciences Institute, Dana Farber, Boston
5Department of Medicine, Boston Univ. School of Med., Boston, MA
6Pharmaxis Ltd, French's Forest, Australia

*signifies non-member of ASH